Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso

Bibliográfalaš dieđut
Váldodahkkit:	Morter, R, Tiono, AB, Nébié, I, Hague, O, Ewer, K, Sirima, SB
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	Frontiers Media 2022

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
Dahkki: Richard Morter, et al.
Almmustuhtton: (2022-12-01)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
Dahkki: Tiono, AB, et al.
Almmustuhtton: (2018)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
Dahkki: Alfred B Tiono, et al.
Almmustuhtton: (2018-01-01)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
Dahkki: Bliss, C, et al.
Almmustuhtton: (2016)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Dahkki: Kimani, D, et al.
Almmustuhtton: (2014)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
Dahkki: Hodgson, S, et al.
Almmustuhtton: (2014)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Dahkki: Ogwang, C, et al.
Almmustuhtton: (2013)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Dahkki: Caroline Ogwang, et al.
Almmustuhtton: (2013-01-01)

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
Dahkki: Rampling, T, et al.
Almmustuhtton: (2018)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
Dahkki: Hodgson, SH, et al.
Almmustuhtton: (2014)

Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP
Dahkki: Rampling, T, et al.
Almmustuhtton: (2016)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
Dahkki: Biswas, S, et al.
Almmustuhtton: (2014)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Dahkki: Elias, S, et al.
Almmustuhtton: (2014)

Hospital-based surveillance of severe paediatric malaria in two malaria transmission ecological zones of Burkina Faso
Dahkki: Alfred B. Tiono, et al.
Almmustuhtton: (2023-01-01)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
Dahkki: Sumi Biswas, et al.
Almmustuhtton: (2014-01-01)

Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso.
Dahkki: Alphonse Ouédraogo, et al.
Almmustuhtton: (2013-01-01)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Dahkki: Mensah, V, et al.
Almmustuhtton: (2016)

Transplacental Transmission of Plasmodium falciparum in a Highly Malaria Endemic Area of Burkina Faso
Dahkki: Alphonse Ouédraogo, et al.
Almmustuhtton: (2012-01-01)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Dahkki: Victorine A Mensah, et al.
Almmustuhtton: (2016-01-01)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
Dahkki: De Barra, E, et al.
Almmustuhtton: (2014)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
Dahkki: Eoghan de Barra, et al.
Almmustuhtton: (2014-01-01)

Seasonal performance of a malaria rapid diagnosis test at community health clinics in a malaria-hyperendemic region of Burkina Faso
Dahkki: Diarra Amidou, et al.
Almmustuhtton: (2012-05-01)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2012)

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2012)

Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso
Dahkki: Diarra Amidou, et al.
Almmustuhtton: (2012-03-01)

Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods.
Dahkki: Alfred B Tiono, et al.
Almmustuhtton: (2014-01-01)

<it>Plasmodium falciparum </it>genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso
Dahkki: Konaté Amadou T, et al.
Almmustuhtton: (2009-06-01)

Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimens
Dahkki: Nébié Issa, et al.
Almmustuhtton: (2009-10-01)

Safety and Immunogenicity of the malaria vaccine candidate R21 adjuvanted with matrix-m1 in West African adult volunteers, Burkina Faso
Dahkki: Tiono, AB, et al.
Almmustuhtton: (2017)

Malariometric Indices in the Context of Seasonal Malaria Chemoprevention in Children Aged 1.5 to 12 Years during the Period of High Malaria Transmission in the Suburban Area of Banfora, Burkina Faso
Dahkki: San M. Ouattara, et al.
Almmustuhtton: (2023-09-01)

Haemoglobin variants and <it>Plasmodium falciparum</it> malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso
Dahkki: Bougouma Edith C, et al.
Almmustuhtton: (2012-05-01)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2011)

Predictors of caregiver adherence to administration of amodiaquine during delivery of seasonal malaria chemoprevention in Nigeria, Burkina Faso, Chad, and Togo
Dahkki: Taiwo Ibinaiye, et al.
Almmustuhtton: (2023-05-01)

Climate impact on malaria in northern Burkina Faso
Dahkki: Yves M. Tourre, et al.
Almmustuhtton: (2017-11-01)

Implementation of Home based management of malaria in children reduces the work load for peripheral health facilities in a rural district of Burkina Faso
Dahkki: Pagnoni Franco, et al.
Almmustuhtton: (2008-10-01)

Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso
Dahkki: Mariama K. Cherif, et al.
Almmustuhtton: (2017-09-01)

Force of Infection (FOI) and Multiplicity of Infection (MOI) in <i>Plasmodium falciparum</i> Infected Children Aged 1.5–12 Years Living in the Malaria Endemic Area of Banfora, Burkina Faso
Dahkki: Emilie S. Badoum, et al.
Almmustuhtton: (2024-10-01)

Social perceptions of malaria and diagnostic-driven malaria treatment in Burkina Faso
Dahkki: Orokia Traore, et al.
Almmustuhtton: (2021-01-01)

Barriers to the quality delivery of seasonal malaria chemoprevention in Chad and Burkina Faso: a qualitative exploration of caregivers and community distributors’ perspectives
Dahkki: Kévin Lasmi, et al.
Almmustuhtton: (2024-07-01)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso

Geahča maid

Geahča maid